Literature DB >> 10699915

Expression of MAGE-antigens in normal tissues and cancer.

A A Jungbluth1, K J Busam, D Kolb, K Iversen, K Coplan, Y T Chen, G C Spagnoli, L J Old.   

Abstract

The human MAGE gene family encodes products that can be recognized by autologous cytotoxic T cells. Because MAGE genes are silent in most normal tissues except testis but are activated in a variety of neoplastic lesions, MAGE antigens represent ideal targets for immunotherapy. Current knowledge of MAGE gene expression is based primarily on mRNA typing and relatively little is known about MAGE protein expression. Monoclonal antibody (MAb) 57B, originally thought to be specific for MAGE-3, but now known to be reactive with other MAGE components, was used in the present study to analyze MAGE expression in a panel of normal and malignant tissues. In tests with a wide range of normal tissues, only spermatogenic cells of testis were reactive with 57B. In tumor tissues, significant immunoreactivity was observed in malignant melanomas and carcinomas of the lung, head and neck as well as urinary bladder. No 57B reactivity was seen with colorectal, prostatic or renal cell carcinomas. Lipo- and myosarcomas, as well as malignant fibrous histiocytoma (MFH), were negative, but synovial sarcomas showed intense immunoreactivity. A subset of seminomas was also strongly reactive with 57B. Tumor specimens showed great variability in the number of tumor cells showing 57B reactivity, with some tumors showing only small isolated clusters of positive cells to other tumors with uniform staining throughout the tumor. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699915

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  58 in total

1.  Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1.

Authors:  Neehar Bhatia; Bing Yang; Tony Z Xiao; Noel Peters; Michael F Hoffmann; B Jack Longley
Journal:  Arch Biochem Biophys       Date:  2011-01-28       Impact factor: 4.013

Review 2.  Cancer/testis antigens and urological malignancies.

Authors:  Prakash Kulkarni; Takumi Shiraishi; Krithika Rajagopalan; Robert Kim; Steven M Mooney; Robert H Getzenberg
Journal:  Nat Rev Urol       Date:  2012-06-19       Impact factor: 14.432

3.  CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.

Authors:  Andrew McLarnon; Karen P Piper; Oliver C Goodyear; Julie M Arrazi; Premini Mahendra; Mark Cook; Fiona Clark; Guy Pratt; Charles Craddock; Paul A H Moss
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

4.  Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

Authors:  Amberly Moreno-Bost; Susann Szmania; Katie Stone; Tarun Garg; Antje Hoerring; Jackie Szymonifka; John Shaughnessy; Bart Barlogie; H Grant Prentice; Frits van Rhee
Journal:  Cytotherapy       Date:  2010-12-20       Impact factor: 5.414

5.  The role of MAGEA2 in head and neck cancer.

Authors:  Chad A Glazer; Ian M Smith; Sheetal Bhan; Wenyue Sun; Steven S Chang; Kavita M Pattani; William Westra; Zubair Khan; Joseph A Califano
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-03

Review 6.  [Expression of cancer testis (CT) antigens in pediatric and adolescent melanomas].

Authors:  N Behrendt; T Schultewolter; K Busam; D Frosina; G Spagnoli; A Jungbluth
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 7.  Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.

Authors:  Yan-Ho Cheng; Elissa Wp Wong; C Yan Cheng
Journal:  Spermatogenesis       Date:  2011-07-01

8.  A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.

Authors:  Yan Yan; Leuyen Phan; Fan Yang; Moshe Talpaz; Yu Yang; Zeyu Xiong; Bernard Ng; Nikolai A Timchenko; Catherine J Wu; Jerome Ritz; Hong Wang; Xiao-Feng Yang
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

9.  MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair.

Authors:  Neehar Bhatia; Tony Z Xiao; Kimberly A Rosenthal; Imtiaz A Siddiqui; Saravanan Thiyagarajan; Brendan Smart; Qiao Meng; Cindy L Zuleger; Hasan Mukhtar; Shannon C Kenney; Mark R Albertini; B Jack Longley
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

Review 10.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Authors:  Michael B Bernstein; Sunil Krishnan; James W Hodge; Joe Y Chang
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.